// App-Quantinova.ai

P377 : Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study

Researchers

Presenter

  • Allez, M

Principal Investigators

  • Lewis, J.D

  • Hanauer, S.B

  • Danese, S

  • Irving, P.M

  • Gasink, C

  • Hoops, T

  • Izanec, J.L

  • Ma, T

  • Loftus- Jr., E.V

  • Scherl, E.J

  • Panaccione, R

  • Sandborn, W.J

  • Sands, B.E

Medical Centers

  • Hôpital Saint-Louis- Assistance Publique-Hôpitaux de Paris AP-HP- INSERM U and Université de Paris, Gastroenterology Department, Paris, France

  • Perelman School of Medicine at the University of Pennsylvania, Division of Gastroenterology, Philadelphia- PA, United States

  • Northwestern University Feinberg School of Medicine, Department of Gastroenterology, Chicago, United States

  • IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Gastroenterology and Endoscopy, Milan, Italy

  • Guy’s and Saint Thomas’ Hospitals NHS Trust, Department of Gastroenterology, London, United Kingdom

  • King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom

  • Janssen Scientific Affairs, LLC, Immunology, Horsham, United States of America

  • Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America

  • Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, Rochester MN, United States

  • New York Presbyterian Hospital Weill Cornell Medicine, Weill Department of Medicine, New York, United States

  • University of Calgary, Inflammatory Bowel Disease Clinic- Division of Gastroenterology and Hepatology of Gastroenterology, Calgary, Canada

  • Univeristy of California San Diego, Division of Gastroenterolgy, San Diego, United States

  • Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States

Locations

  • France

  • United States

  • Italy

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

  • Adalimumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved